United Therapeutics (UTHR)
(Delayed Data from NSDQ)
$397.49 USD
+14.72 (3.85%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $397.55 +0.06 (0.02%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth C Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$397.49 USD
+14.72 (3.85%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $397.55 +0.06 (0.02%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth C Momentum A VGM
Zacks News
United Therapeutics' (UTHR) Tyvaso DPI NDA Gets CRL From FDA (Revised)
by Zacks Equity Research
United Therapeutics' (UTHR) new drug application for Tyvaso DPI to treat PAH & PH-ILD fails to secure approval from the FDA. The stock declines resultantly.
United Therapeutics' (UTHR) Tyvaso DPI NDA Gets CRL From FDA
by Zacks Equity Research
United Therapeutics' (UTHR) new drug application for Tyvaso DPI to treat PAH & PH-ILD fails to secure approval from the FDA. The stock declines resultantly.
United Therapeutics (UTHR) Up 3.4% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
United Therapeutics (UTHR) Q2 Earnings & Sales Beat, Stock Up
by Zacks Equity Research
United Therapeutics (UTHR) second-quarter earnings and sales beat estimates. Higher sales of Orenitram, Unituxin and Tyvaso mainly drive the top line in the quarter.
United Therapeutics (UTHR) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
United Therapeutics (UTHR) delivered earnings and revenue surprises of 27.62% and 17.66%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
United Therapeutics (UTHR) to Report Q2 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
United Therapeutics (UTHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3D Systems (DDD) Joins CollPlant for Bioprinted Breast Tissue Matrix
by Zacks Equity Research
The collaborative efforts of 3D Systems (DDD) and CollPlant aim to eliminate the odds of adverse immune response in the human body induced by procedures using tissue derived from humans and animals.
United Therapeutics (UTHR) Tyvaso DPI Gets FDA's Priority Tag
by Zacks Equity Research
United Therapeutics' (UTHR) Tyvaso DPI is a drug device combination therapy, comprising the dry powder formulation of Tyvaso and a small, portable, dry powder inhaler.
Why Is United Therapeutics (UTHR) Down 8.8% Since Last Earnings Report?
by Zacks Equity Research
United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
United Therapeutics (UTHR) Begins TETON Study on Tyvaso in IPF
by Zacks Equity Research
United Therapeutics (UTHR) enrolls the first patient in the phase III TETON study evaluating Tyvaso for treating adult patients with idiopathic pulmonary fibrosis.
United Therapeutics (UTHR) Q1 Earnings Miss, Sales Beat
by Zacks Equity Research
United Therapeutics (UTHR) reports mixed first-quarter 2021 results. Higher sales of Orenitram, Unituxin and Tyvaso offset lower sales of Remodulin and Adcirca.
United Therapeutics (UTHR) Lags Q1 Earnings Estimates
by Zacks Equity Research
United Therapeutics (UTHR) delivered earnings and revenue surprises of -76.54% and 3.37%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: United Therapeutics (UTHR) Q1 Earnings Expected to Decline
by Zacks Equity Research
United Therapeutics (UTHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
United Therapeutics (UTHR) Gains on Tyvaso Label Expansion
by Zacks Equity Research
United Therapeutics' (UTHR) Tyvaso is now the only FDA-approval therapy for treating serious, life-threatening disease, pulmonary hypertension associated with interstitial lung disease.
Why Is United Therapeutics (UTHR) Down 0.3% Since Last Earnings Report?
by Zacks Equity Research
United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
United Therapeutics (UTHR) Q4 Earnings Miss, Sales Beat
by Zacks Equity Research
United Therapeutics' (UTHR) fourth-quarter earnings miss estimates while sales beat the same. Higher sales of Orenitram, Remodulin and Tyvaso offset lower sales of Unituxin and Adcirca.
United Therapeutics (UTHR) Misses Q4 Earnings Estimates
by Zacks Equity Research
United Therapeutics (UTHR) delivered earnings and revenue surprises of -26.26% and 8.12%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
United Therapeutics (UTHR) Earnings Expected to Grow: What to Know Ahead of Q4 Release
by Zacks Equity Research
United Therapeutics (UTHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aclaris (ACRS) Up on Preliminary Data for MK2 Inhibitor in RA
by Zacks Equity Research
Aclaris (ACRS) posts favorable preliminary topline results from a phase IIa study evaluating its investigational oral candidate ATI-450 for treating moderate to severe rheumatoid arthritis. Shares up.
RedHill's (RDHL) RHB-204 Gets FDA Fast Track Designation
by Zacks Equity Research
RedHill (RDHL) gets Fast Track status from the FDA for the treatment of nontuberculous mycobacteria (NTM) disease.
United Therapeutics (UTHR) Up 2.3% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Liquidia (LQDA) PAH Drug Gets FDA's Complete Response Letter
by Zacks Equity Research
The CRL issued to the NDA for Liquidia's (LQDA) LIQ861 stated that the FDA cannot approve the NDA in its present form
United Therapeutics (UTHR) Q3 Earnings & Sales Beat Estimates
by Zacks Equity Research
United Therapeutics' (UTHR) third-quarter earnings and sales beat estimates. Higher sales of Orenitram and Tyvaso offset lower sales of Remodulin and Adcirca.
United Therapeutics (UTHR) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
United Therapeutics (UTHR) delivered earnings and revenue surprises of 59.34% and 5.01%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Drug/Biotech Stock Q3 Earnings on Oct 28: GSK, AMGN & More
by Zacks Equity Research
Let us take a look at four drug/biotech companies due to release their quarterly results on Oct 28.